TACE COMPLICATIONS
RECOGNITION AND MANAGEMENT
Major TACE complications — hepatic decompensation, liver abscess, biliary injury, and hepatic artery damage — occur in approximately 5–10% of procedures. Most are avoidable with careful patient selection and manageable when recognised early. Understanding the complication landscape helps patients consent fully and seek help at the right moment.
analyticsAt a Glance
- check_circleMajor complication rate: 5–10% across published TACE series — significantly lower at high-volume specialist centres
- check_circleHepatic decompensation is the most clinically significant complication — primarily a selection failure in Child-Pugh B8+ patients
- check_circleLiver abscess risk is substantially higher in patients with prior biliary intervention (bilioenteric anastomosis, sphincterotomy, biliary stent)
- check_circle30-day mortality from procedure-related complications: <2% at high-volume centres; higher at low-volume programmes
Understanding the TACE Complication Spectrum
TACE complications fall into two broad categories: those that are primarily selection failures — occurring because the procedure was performed in a patient who should not have received it — and those that are procedural events that can occur even in appropriately selected patients. Most of the first category (hepatic decompensation, fatal liver failure) are preventable through rigorous application of Child-Pugh and BCLC selection criteria. Most of the second category (liver abscess, biliary injury, hepatic artery injury) are manageable when detected early.
“The most dangerous TACE complication — acute liver decompensation — is almost always a selection failure, not a procedural failure. It occurs when TACE is performed in patients whose liver reserve cannot withstand the additional insult of arterial embolisation.”
Selection-Preventable Complications
Hepatic decompensation, acute liver failure, and encephalopathy occur predominantly in patients with Child-Pugh B8–C, advanced portal hypertension, or extensive hepatic tumour burden (>50% liver volume). Rigorous application of selection criteria reduces — but does not eliminate — these events. Every borderline case should be reviewed at a specialist hepatobiliary MDT.
Procedure-Related Complications
Liver abscess, biliary injury, hepatic artery dissection or injury, non-target embolisation, and femoral access complications can occur in appropriately selected patients. These are operator and centre quality-dependent — complication rates for liver abscess, biliary injury, and hepatic artery events are 30–50% lower at high-volume programmes compared to low-volume centres.
TACE Complications: Reference Table
A comprehensive overview of major TACE complications — with frequency, primary risk factors, clinical presentation, and management.
| Complication | Frequency | Primary Risk Factors | Presentation | Management |
|---|---|---|---|---|
| Hepatic decompensation | 2–5% | Child-Pugh B8+; large tumour volume; portal hypertension; prior decompensation episodes | Worsening jaundice; new or worsening ascites; encephalopathy; rising bilirubin; falling albumin within days–weeks post-TACE | Supportive hepatology: IV albumin; diuretics for ascites; lactulose for encephalopathy; nutritional support; transplant evaluation escalation if listed |
| Acute liver failure | 0.5–2% | Child-Pugh C (procedure contraindicated); very high PES; massive tumour volume ablated | Rapid-onset coagulopathy; encephalopathy; jaundice; renal impairment; rising lactate — same-day deterioration | ICU; N-acetylcysteine; liver support if available; emergency transplant evaluation; mortality high |
| Liver abscess | 1–2% | Prior biliary intervention (sphincterotomy, bilioenteric anastomosis, biliary stent); Oddi sphincter incompetence; diabetes mellitus | Fever >38.5°C after Day 5; rising CRP/WBC; RUQ pain; CT shows ring-enhancing collection | IV broad-spectrum antibiotics (piperacillin-tazobactam); CT-guided percutaneous aspiration/drainage; prolonged antibiotic course 4–6 weeks; prophylactic antibiotics at TACE recommended for high-risk patients |
| Biloma / bile duct injury | 0.5–1.5% | Superselective catheterisation near intrahepatic bile ducts; DEB-TACE near central bile ducts; prior biliary surgery | RUQ pain; cholangitis features; CT shows peri-biliary fluid collection; rising bilirubin | Percutaneous biloma drainage; ERCP ± biliary stent if obstruction; antibiotics for cholangitis; conservative if small and asymptomatic |
| Cholecystitis / gallbladder infarction | 1–2% | Non-target embolisation of cystic artery; gallbladder bed tumour | RUQ pain with guarding; fever; raised WBC; CT shows gallbladder wall thickening/pneumobilia | IV antibiotics; percutaneous cholecystostomy; cholecystectomy if perforation |
| Hepatic artery injury (dissection/thrombosis) | 0.5–1% | Atherosclerosis; repeated catheterisations; aggressive wire manipulation | Abrupt loss of flow on final arteriogram; post-TACE ischaemia; rising LFTs; biliary ischaemia | Conservative if flow maintained; re-catheterisation and thrombolysis rarely; interventional radiology revision |
| Non-target embolisation | Rare (<0.5%) | Reflux of embolic material; variant hepatic arterial anatomy not identified | Pain in non-hepatic territory (gastric, splenic, duodenal, colonic); imaging confirms target organ ischaemia | Conservative for splenic; surgical consultation for bowel perforation; proton pump inhibitors for gastric involvement |
| Femoral access complications | 1–2% | Arterial disease; obesity; anticoagulation; puncture technique | Haematoma at puncture site; pseudoaneurysm (pulsatile mass); AV fistula (machinery bruit) | Manual compression; ultrasound-guided thrombin injection for pseudoaneurysm; surgical repair if large |
| Contrast nephropathy | 1–3% | Pre-existing CKD; diabetes; dehydration; large contrast volume | Creatinine rise within 48–72 hours; oliguria in severe cases | IV pre-hydration; minimise contrast; N-acetylcysteine in high-risk patients; nephrology consultation if severe |
Prevention Strategies for High-Risk Complications
Most major TACE complications are preventable or mitigatable with specific pre-procedural measures — particularly for patients with known risk factors.
- 1
Prior Biliary Intervention — Antibiotic Prophylaxis
Patients with prior bilioenteric anastomosis (Whipple, hepaticojejunostomy), ERCP with sphincterotomy, or biliary stent have disrupted Oddi sphincter function — allowing enteric bacteria to colonise the bile ducts. TACE in these patients carries a 10–20× higher liver abscess risk. Prevention: pre-procedural biliary decontamination and broad-spectrum antibiotics (ciprofloxacin + metronidazole) starting 24 hours before TACE and continuing for 5–7 days post-TACE. Consider oral antibiotic prophylaxis throughout the treatment course.
- 2
Child-Pugh B7: Reduced Procedure Intensity
Child-Pugh B7 patients are eligible for TACE but have reduced hepatic reserve. Prevention strategy: superselective (subsegmental) rather than lobar TACE to minimise the volume of normal liver exposed to embolisation; limit chemotherapy dose per session; plan multiple smaller sessions rather than one large session; use DEB-TACE if available (lower hepatotoxicity than cTACE).
- 3
Portal Vein Involvement — Partial or Absent Embolisation
When partial portal vein involvement exists (segmental rather than main PVTT), TACE can be performed but with reduced embolisation — chemotherapy infusion only (HAIC-like) without embolic material in the most affected segments. This reduces ischaemia risk while delivering chemotherapy.
- 4
Diabetes Mellitus — Blood Glucose Optimisation
Diabetic patients have impaired hepatic immune defences and are at higher liver abscess risk. Optimise glycaemic control before TACE (HbA1c <8% if possible); monitor blood glucose closely post-procedure; antibiotics on low threshold for fever investigation.
- 5
Renal Impairment — Pre-Hydration and Contrast Minimisation
Patients with CKD (GFR <60 mL/min) require IV pre-hydration (0.9% NaCl at 1 mL/kg/hr for 3–6 hours before and after) and minimised contrast volume (iso-osmolar contrast preferred; CO2 angiography if available to reduce iodinated contrast use).
TACE Complications: Key Reference Numbers
Published complication rates from high-volume TACE programmes.
- 5–10%Major complication rate across published TACE seriesRates at high-volume specialist centres (>100 TACE/year) are consistently below this range — operator and programme experience directly reduces complication risk.
- <2%30-day procedure-related mortality at high-volume centresPatient selection quality and procedural expertise at specialist programmes achieves mortality rates well below population series averages.
- 10–20×Increased liver abscess risk in patients with prior biliary interventionThe most modifiable and frequently overlooked TACE complication risk factor — prophylactic antibiotics and biliary decontamination are mandatory in this group.
- 50%Reduction in complication rates: high-volume vs low-volume centresVolume-outcome relationship for TACE is well-established — centres performing fewer than 20 cases per year have significantly higher complication rates.
More from the TACE Resource Library
Continue exploring TACE — from post-embolisation syndrome to repeat TACE decisions and patient experience.
- Post-Embolisation Syndrome: What to Expect After TACE
- TACE Patient Selection: BCLC Staging and Child-Pugh Score
- Repeat TACE: When to Retreat and When to Stop
- mRECIST Response Assessment for TACE: How Response Is Measured
- TACE Therapy — Complete Treatment Guide
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
Frequently Asked Questions
Common questions about TACE complication risk and prevention.
About TACE Safety
I have a biliary stent from a previous procedure — does this increase my TACE complication risk?
Yes — significantly. A biliary stent or any prior biliary intervention that disrupts the sphincter of Oddi (ERCP, sphincterotomy, bilioenteric anastomosis, percutaneous biliary drainage) allows enteric bacteria to colonise the bile ducts. When TACE is performed in this context, embolisation of the bile duct microvasculature creates small areas of biliary ischaemia — and in the presence of colonised bile ducts, these become infected, forming liver abscesses with 10–20× the frequency of patients without biliary intervention history. The management is not to avoid TACE but to use prophylactic antibiotics starting 24 hours before the procedure and continuing 5–7 days after, targeting enteric organisms (ciprofloxacin + metronidazole is a standard regimen). Inform your interventional radiologist of all prior biliary procedures at the pre-TACE consultation.
What is the difference between post-embolisation syndrome and a TACE complication?
Post-embolisation syndrome (PES) is an expected, self-limiting inflammatory response to tumour ischaemia — fever up to 39°C, RUQ pain or aching, nausea, and fatigue in the first 3–7 days. It requires supportive care (paracetamol, antiemetics, IV fluids) but not urgent medical intervention. A complication is a pathological event that exceeds expected PES — liver abscess (fever persisting beyond Day 5 with rising CRP, new collection on CT), biliary injury (developing jaundice, cholangitis), hepatic decompensation (progressive jaundice, ascites, encephalopathy), or access site complications (pseudoaneurysm). The key red flags that distinguish complication from PES: fever above 38.5°C persisting beyond Day 5; worsening rather than improving pain beyond Day 3; new jaundice developing after initial improvement; any neurological change (confusion); or symptoms at a distant anatomical site.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Concerned About TACE Safety for Your Case?
CancerFax reviews your Child-Pugh score, biliary history, portal vein status, and prior treatments to identify complication risk factors — and connects you with high-volume TACE centres in China and India where complication rates are consistently below population averages.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.